Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(1)
Other(3)

Detailed Status

unknown3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (75.0%)
Phase 31 (25.0%)

Trials by Status

terminated125%
unknown375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

NCT05263999
unknownphase_1

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

NCT05986162
unknownphase_1

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

NCT05978544
unknownphase_1

Safety and Clinical Activity of Itolizumab in aGVHD

NCT05823675

Clinical Trials (4)

Showing 4 of 4 trials
NCT05263999Phase 3

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Terminated
NCT05986162Phase 1

Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis

Unknown
NCT05978544Phase 1

Safety and Preliminary Clinical Activity of Itolizumab in ARDS

Unknown
NCT05823675Phase 1

Safety and Clinical Activity of Itolizumab in aGVHD

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4